Northerner
Admin (Retired)
- Relationship to Diabetes
- Type 1
The prospect of remission of type 2 diabetes (T2D) has captured the hearts and minds of many patients with T2D and healthcare professionals, including myself.
Kevin Fernando, MBChB, MSc
I have changed my narrative when supporting my patients with T2D. I used to say that T2D is a progressive condition, but considering seminal recent evidence like the DiRECT trial, I now say that T2D can be a progressive condition. Through significant weight loss, patients can reverse it and achieve remission of T2D. This has given my patients hope that their T2D is no longer an inexorable condition. And hope, of course, is a powerful enabler of change.
However, the million-dollar question is whether remission of T2D can be maintained in the long term in the real-world setting of primary care, which is chiefly where T2D is managed.
I therefore relished the opportunity to attend a debate on this topic at the 59th EASD Annual Meeting in Hamburg, Germany, between Roy Taylor, MD, principal investigator for the DiRECT study and professor of medicine and metabolism at the University of Newcastle, United Kingdom, and Kamlesh Khunti, MD, PhD, professor of primary care diabetes at the University of Leicester, United Kingdom.
Kevin Fernando, MBChB, MSc
I have changed my narrative when supporting my patients with T2D. I used to say that T2D is a progressive condition, but considering seminal recent evidence like the DiRECT trial, I now say that T2D can be a progressive condition. Through significant weight loss, patients can reverse it and achieve remission of T2D. This has given my patients hope that their T2D is no longer an inexorable condition. And hope, of course, is a powerful enabler of change.
However, the million-dollar question is whether remission of T2D can be maintained in the long term in the real-world setting of primary care, which is chiefly where T2D is managed.
I therefore relished the opportunity to attend a debate on this topic at the 59th EASD Annual Meeting in Hamburg, Germany, between Roy Taylor, MD, principal investigator for the DiRECT study and professor of medicine and metabolism at the University of Newcastle, United Kingdom, and Kamlesh Khunti, MD, PhD, professor of primary care diabetes at the University of Leicester, United Kingdom.
Is Lasting Remission of T2D Feasible in the Real World?
Tantalizing data suggest that remission is achievable, but how long can it be maintained?
www.medscape.com